{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:45:02Z","timestamp":1790045102399,"version":"4.0.1"},"reference-count":30,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Gene Therapies"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Market Access &amp; Health Policy"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1080\/20016689.2021.1889841","type":"journal-article","created":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T12:15:11Z","timestamp":1614514511000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":48,"title":["An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)"],"prefix":"10.3390","volume":"9","author":[{"given":"Rebecca","family":"Dean","sequence":"first","affiliation":[{"name":"HEOR, Precision Xtract, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivar","family":"Jensen","sequence":"additional","affiliation":[{"name":"HEOR, Precision Xtract, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Cyr","sequence":"additional","affiliation":[{"name":"HEOR, Precision Xtract, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beckley","family":"Miller","sequence":"additional","affiliation":[{"name":"HEOR, Precision Xtract, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benit","family":"Maru","sequence":"additional","affiliation":[{"name":"Medical Consulting, SSI Strategy, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Sproule","sequence":"additional","affiliation":[{"name":"Global HEOR & RWE, Novartis Gene Therapies, Bannockburn, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Feltner","sequence":"additional","affiliation":[{"name":"Global HEOR & RWE, Novartis Gene Therapies, Bannockburn, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Business Consulting, SSI Strategy, Parsippany, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Malone","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bischof","sequence":"additional","affiliation":[{"name":"Global HEOR & RWE, Novartis Gene Therapies, Bannockburn, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Toro","sequence":"additional","affiliation":[{"name":"Global HEOR & RWE, Novartis Gene Therapies, Bannockburn, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Dabbous","sequence":"additional","affiliation":[{"name":"Global HEOR & RWE, Novartis Gene Therapies, Bannockburn, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,28]]},"reference":[{"key":"cit0001","unstructured":"ZOLGENSMA (Onasemnogene abeparvovec) PI. In: Administration UFaD, ed2019."},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0724-z"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.09.015"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000741"},{"key":"cit0006","unstructured":"Services. DoHaH. Recommended Uniform Screening Panel (2018, July). In: Services. DoHaH, ed2018."},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.06.007"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24203"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1601484"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(96)00284-5"},{"key":"cit0012","volume-title":"Cure SMA Annual Meeting","author":"Shieh PB","year":"2017"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-2278"},{"key":"cit0014","unstructured":"(ICER) IfCaER.\n                      Spinraza and Zolgensma for Spinal Muscular Atrophy: Effectiveness and Value. Final Evidence Report\n                      . April 3, 2019 (Updated May 24, 2019) 2019."},{"key":"cit0015","unstructured":"Review IIfCaE.\n                      Modifications to the ICER value assessment framework for treatments for ultra-rare diseases\n                      . November 2017 2017."},{"key":"cit0016","volume-title":"Longer-term assessment of the safety and efficacy of nusinersen for the treatment of infantile-onset Spinal Muscular Atrophy (SMA): an interim analysis of the SHINE study. American academy of neurology","author":"Castro D","year":"2018"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25101"},{"key":"cit0019","volume-title":"ISPOR 20TH Annual European Congress 4\u20138 November 2017","author":"Thompson R","year":"2017"},{"key":"cit0020","unstructured":"Tappenden P, Hamilton J, Kaltenthaler E, et al. Nusinersen for treating spinal muscular atrophy: a single technology appraisal. School of Health and Related Research (ScHARR); 2018."},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2524.2006.00639.x"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.05.005"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017010645"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.004"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1089\/pai.2009.0002"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00923-8"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.01.012"},{"key":"cit0028","volume-title":"22nd Annual SMA Researcher Meeting","author":"Mendell JR","year":"2018"},{"key":"cit0029","unstructured":"Database USM. Human mortality database. 2017; https:\/\/usa.mortality.org\/"},{"key":"cit0030","unstructured":"The Lewis Group Inc. Cost of amyotrophic lateral sclerosis, muscular dystrophy, and spinal muscular atrophy in the USA. 2012; https:\/\/www.mda.org\/sites\/default\/files\/Cost_Illness_Report_0.pdf"}],"container-title":["Journal of Market Access &amp; Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20016689.2021.1889841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T04:03:04Z","timestamp":1705550584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/search?q=10.1080\/20016689.2021.1889841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"alternative-id":["10.1080\/20016689.2021.1889841"],"URL":"https:\/\/doi.org\/10.1080\/20016689.2021.1889841","relation":{},"ISSN":["2001-6689"],"issn-type":[{"value":"2001-6689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=zjma20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=zjma20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1889841"}}